alexa Exogenous Truncated IK Protein Ameliorates Inflammatory Arthritis By HIF-1α Induced A20
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th European Immunology Conference
June 29-July 01, 2017 Madrid, Spain

Jae-Hwan Nam, Seo-Yeon Chung, Suelgi Choi and Hye-Lim Park
Catholic University of Korea, South Korea
Posters & Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899-C1-037
Abstract
IK protein was first isolated from the cultured media of K562, leukemia cell line. It is known as an inhibitory regulator of constitutive and interferon-γ-induced major histocompatibility complex (MHC) class II expression. Previously, we found the reduction of pathogenic Th17 cells that have been known to be involved in the development of rheumatoid arthritis (RA), in polarizing condition in the truncated IK (tIK)-transgenic (Tg) mice as compared with that in the wild type (WT) Balb/c mice. Based on this finding, we investigated the therapeutic effect and protection mechanism of exogenous tIK protein produced by insect expression system for the RA mouse disease model (collagen antibody-induced arthritis, CAIA). Injection of tIK protein alleviated the symptoms of RA and reduced Th17 cell population in the CAIA model. Interestingly, the computer modeling structure of IK protein is similar to IL- 10 structure. It can be speculated that tIK protein may belong to the IL-10 protein family. In addition, treatment of tIK protein on cultured T cells induced A20, as a negative regulator in NFκB pathway, through hypoxia-inducible factor-1α (HIF-1α) and reduced several transcriptional factors related to T cell activation. Based on these results, we suggest that tIK protein has a potential to act as a new therapeutic agent for RA patients, because it has a different mode of action as compared with the currently used biologics for RA, such as monoclonal antibody drugs.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version